Glenmark Brand Guidelines: A 1977 Mumbai Generics Maker Named for Glenn and Mark

A family name made from two sons.

Glenmark began in Mumbai in 1977. English Wikipedia says Gracias Saldanha founded it as a maker of generic drugs and active pharmaceutical ingredients, that the company was incorporated on 18 November 1977, and that its name was made from the names of his two sons, Glenn and Mark. Its first markets, the same article says, were India, Russia and Africa.

Several of its oldest names are Indian brands. English Wikipedia dates the antifungal Candid to 1979 and lists Ascoril and La Shield among the company’s Indian brands; the cardiovascular brand Telma followed in 2003. In March 2020 Glenmark sold the VWash intimate-hygiene brand to Hindustan Unilever, and in August 2025 it moved its consumer products into a subsidiary, Glenmark Consumer Care Limited, the article says.

The company went public on Indian exchanges in 1999 and is listed on the Bombay Stock Exchange and the National Stock Exchange of India. Glenn Saldanha became managing director in 2001, after working at Eli Lilly and PricewaterhouseCoopers, according to English Wikipedia; in the company’s 2025 press releases he is quoted as Chairman and Managing Director. Its head office, Glenmark House, is in Andheri East, Mumbai, according to its stock-exchange filings.

From generics to licensed research.

From the mid-2010s Glenmark moved from generics towards medicines of its own in oncology, dermatology and respiratory care, English Wikipedia says, developing drugs in-house and licensing some of them to larger companies. Its website now calls it “a research-led, global pharmaceutical company” with branded, specialty, generic and consumer products, and names respiratory, dermatology and oncology as its focus areas. One of its own products is Ryaltris, a nasal spray that it launched in the United States in 2022, according to English Wikipedia.

In January 2024 Glenmark and its subsidiary Ichnos Sciences formed Ichnos Glenmark Innovation (IGI) to bring its oncology drug discovery together, English Wikipedia says; Glenmark’s own releases describe IGI as based in New York. Later in 2024 Glenmark sold a 75 percent stake in its subsidiary Glenmark Life Sciences to Nirma, the same article records.

2025 was a year of licensing agreements. On 10 July 2025 IGI and AbbVie announced an exclusive global licensing agreement for ISB 2001, a trispecific antibody then in a Phase 1 trial in multiple myeloma, according to the release Glenmark filed with the Indian stock exchanges that day. On 24 September 2025 Glenmark’s subsidiary Glenmark Specialty S.A. announced an exclusive licence from Hengrui Pharma for the HER2-targeting antibody-drug conjugate trastuzumab rezetecan, covering markets outside mainland China, the United States, Canada, Europe, Japan, Russia and a list of other excluded countries, according to Glenmark’s release. On 16 December 2025 the same subsidiary announced rights from Hansoh Pharma to the lung-cancer medicine aumolertinib for the Middle East and Africa, South and Southeast Asia, Australia, New Zealand and Russia and the CIS, according to Glenmark’s release.

In November 2025 Glenmark launched in India a nebulised combination of glycopyrronium, formoterol and budesonide for chronic obstructive pulmonary disease, sold as Nebzmart GFB Smartules and Glenmark Airz FB Smartules, which the company described in its release of 25 November 2025 as “the world’s first nebulized, fixed-dose triple therapy” for the condition.

Much of its cancer range is licensed in. English Wikipedia lists Tevimbra and Brukinsa, which it distributes for BeiGene, and envafolimab, sold as QiNHAYO in India and selected emerging markets under a licence from Jiangsu Alphamab and 3D Medicines. In dermatology, the acne cream Winlevi received European Commission approval in December 2025, with Glenmark holding distribution rights in 17 European Union countries, the article says; in diabetes, Glenmark launched the biosimilars Lirafit in January 2024 and Glipiq in March 2026.

Design and documentation.

India’s drug makers are spread across several states, and some regions have become clusters. English Wikipedia’s article on the pharmaceutical industry in Gujarat calls Ahmedabad and Vadodara the state’s pharmaceutical hubs and records that the state government declared Gujarat a “pharma hub” in 2000; Torrent Pharma’s plants at Chhatral and Dahej are in the same state. Glenmark’s August 2026 factsheet lists formulation plants in Goa, Sikkim, Madhya Pradesh, Himachal Pradesh and Maharashtra, as well as in Argentina, the United States and the Czech Republic.

Many of the companies in this guide began as family firms and still carry their founders’ stories. Glenmark’s name, English Wikipedia says, was made from the names of its founder’s two sons; Torrent Pharma started in 1959 as Trinity Laboratories and belongs to a group that also runs power and gas businesses. Where a company’s history rests only on its own website, this guide says so.

The industry has its own meeting places. CPHI India, the Informa trade fair that bills itself as “the heart of South Asia’s pharma,” runs from 23 to 26 November 2026 at the IICC in Delhi, alongside the PMEC India machinery show at Greater Noida, according to its website. DCAT Week, which calls itself “the premier event for the global bio/pharmaceutical business ecosystem,” is next held in New York City from 15 to 18 March 2027.

This guide looks at how each company presents itself — in plant photographs, laboratory imagery, packs, founder portraits and corporate colours — and sets out what can be checked about each one: who founded it, who owns it and where it says its medicines are made, marking clearly what rests only on the company’s own word.

Eleven plants on four continents.

Glenmark says it runs eleven manufacturing sites. Its factsheet, last updated on 5 August 2026, places formulation plants in India at Goa, Sikkim, Indore, Nalagarh, Baddi, Nashik and Chhatrapati Sambhajinagar, and outside India at Pilar in Argentina, Monroe in North Carolina and Vysoké Mýto in the Czech Republic. The Czech site came with the purchase of Medicamenta in 2007, and the oldest plant, in Maharashtra, opened in 1983, according to English Wikipedia. The factsheet lists research centres at Sinnar, Mahape and Taloja in India, at Lausanne and Neuchâtel in Switzerland, and in New York.

On 27 November 2025 Glenmark said the US Food and Drug Administration had classified a June 2025 inspection of its Monroe plant as “Voluntary Action Indicated” and that it would restart commercial manufacturing there. The same factsheet says the company works in more than 80 countries.

Its stated values are Achievement, Respect and Knowledge, and its stated vision is “to emerge as a leading, research-led, global pharmaceuticals Company.”

For a design guide, Glenmark shows how a family-named generics maker can recast itself as a research-led brand without changing its name. Compare Cipla, founded in Bombay in 1935, and Torrent Pharma, part of an Ahmedabad group run by its founder’s sons. For this guide we use a deep indigo and a saffron with a sans, an unofficial interpretation; no product or logo is reproduced.

Keep Glenmark’s identity on hand — save it to a board in the Made Good inspiration library.